CVE-2020-15809

CVE-2020-15809 is a medium-severity vulnerability in Spinetix Dsos with a CVSS 3.x base score of 6.5. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-22.

Key facts

Description

spxmanage on certain SpinetiX devices allows requests that access unintended resources because of SSRF and Path Traversal. This affects HMP350, HMP300, and DiVA through 4.5.2-1.0.36229; HMP400 and HMP400W through 4.5.2-1.0.2-1eb2ffbd; and DSOS through 4.5.2-1.0.2-1eb2ffbd.

Frequently asked questions

What is CVE-2020-15809?
spxmanage on certain SpinetiX devices allows requests that access unintended resources because of SSRF and Path Traversal. This affects HMP350, HMP300, and DiVA through 4.5.2-1.0.36229; HMP400 and HMP400W through 4.5.2-1.0.2-1eb2ffbd; and DSOS through 4.5.2-1.0.2-1eb2ffbd.
How severe is CVE-2020-15809?
CVE-2020-15809 has a CVSS 3.x base score of 6.5, rated medium severity. It is exploitable over network with low attack complexity, requires low privileges and no user interaction. Impact on confidentiality is high, integrity none, and availability none.
Is CVE-2020-15809 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (57th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2020-15809?
CVE-2020-15809 primarily affects Spinetix Dsos. In total, 6 product configurations (CPEs) are listed as vulnerable; see the affected-products list for the exact versions.
How do I fix CVE-2020-15809?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround.
When was CVE-2020-15809 published?
CVE-2020-15809 was published on 2021-03-24 and last updated on 2026-06-17.

References

Affected products (6)

Other CWE-22 (Path Traversal) vulnerabilities

Browse all CWE-22 (Path Traversal) vulnerabilities →